Cannara completes Valleyfield building sale for $5.5M

Executive Summary

• Cannara Biotech Inc. has completed the sale of a non-core building under construction and a related parcel of land at its Valleyfield site for total gross proceeds of $5.5 million.
• The transaction is part of the company's previously announced asset optimization plan and capital discipline strategy, aimed at improving operational efficiency and financial flexibility.
• Net proceeds of $5.45 million will be used to reduce the principal balance of the company's existing term loan, thereby decreasing long-term debt without altering existing credit facility terms.

Key Details

• Transaction Value: Total proceeds of $5.5 million.
• Assets Sold: A non-core building under construction and a related parcel of land located at the company's Valleyfield site.
• Carrying Value: The assets had a carrying value of $4,951,165 as of May 31, 2025, and were classified as held for sale.
• Use of Proceeds: Net proceeds of $5.45 million applied to reduce the principal balance of the existing term loan.
• Debt Impact: The transaction effectively decreases the company's long-term debt; no other changes to the terms of existing credit facilities.
• Strategic Context: Part of an asset optimization plan announced in January 2024 to divest unused land and adjacent buildings initially intended for lease.
• Company Profile: Cannara Biotech is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products in Canada, operating two mega facilities in Quebec with 100,000 kilograms of potential annualized cultivation output.

Notable Quotes

• "This transaction reflects our disciplined execution of Cannara's long-term strategy to unlock value from underutilized assets while preserving financial flexibility," said Zohar Krivorot, president and chief executive officer.
• "Reducing our debt by $5.45-million further enhances Cannara's capital structure and supports future margin expansion," added Nicholas Sosiak, chief financial officer.